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country). Patient inclusion criteria were: C-HCV diagnosis within past 5 years; treated 
with peginterferon alfa-2a or alfa-2b plus ribavirin combination therapy (PEG2A+R 
or PEG2B+R, respectively); age ≥18 years; no diagnoses of hepatitis B or HIV/AIDS; 
≥1 year follow-up post-treatment initiation; no clinical trial participation. Treatment 
dosing, duration, compliance, and costs (in 2009 3) were descriptively analyzed at the 
patient level. Published drug prices were used in all cost calculations. RESULTS: 
Hepatology, gastroenterology, and internal medicine were the predominant physician 
specialties observed, representing 22%, 30%, and 25%, respectively, of all physicians 
recruited. A total of 804 patients (∼160 per country) were identiﬁed, of whom 65% 
were male with mean age of 46 years. More patients initiated PEG2A+R (69%) than 
PEG2B+R (31%). For both regimens, all major ribavirin doses (800, 1000, and 
1200 mg) were seen, representing 36%, 35%, and 22%, respectively, of PEG2A+R 
patients and 39%, 47%, and 14%, respectively, of PEG2B+R patients. Mean treat-
ment duration was ∼35 weeks for both PEG2A+R and PEG2B+R, with distribution 
spikes at 24 and 48 weeks. Treatment compliance was relatively high, with ∼75% of 
patients completing therapy as planned regardless of regimen. Mean weekly treatment 
costs ranged from 3280 to 3350 depending on the ribavirin dose. Mean total regimen 
costs were estimated at 311,827 and 311,109 per patient for PEG2A+R and PEG2B+R, 
respectively. CONCLUSIONS: Peginterferon-based regimens, although a mainstay of 
C-HCV management, are costly. Public health systems bearing the high economic 
burden of C-HCV treatment should be mindful of these costs when considering for-
mulary access for alternative treatments.
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OBJECTIVES: 1. Identify a comprehensive set of symptoms for measurement in CC 
clinical trials. 2. Achieve saturation and provide support for the content validity of 
the corresponding set of endpoints in accordance with FDA’s PRO guidance. 
METHODS: Twenty-eight in-depth interviews were conducted in two phases, in dif-
ferent geographic locations, with participants meeting modiﬁed Rome II criteria for 
CC. A semi-structured interview guide was used, beginning with a series of open-ended 
questions to elicit all relevant symptoms, followed by interviewer probes to fully 
understand the relationships among the concepts. Multiple rating and ranking 
methods were used to develop a subset of CC symptoms of greatest importance to 
patients. For example, participants were asked to identify their most bothersome CC 
symptoms, as well as those in which they would most like to see an improvement with 
treatment. RESULTS: When asked to describe their CC symptoms, the patients 
reported 62 potentially distinct concepts: 12 bowel symptoms, 21 abdominal symp-
toms, 25 additional physical symptoms, and 4 mental or emotional issues. Patient 
descriptions of symptoms revealed that symptom terms were highly related and/or 
could be considered secondary to CC. Results of the subsequent rating and ranking 
tasks suggest that the concepts of stool frequency, stool consistency, straining, incom-
plete evacuation, abdominal pain, abdominal discomfort, and bloating were distinct 
and comprise patients’ most bothersome symptoms. Further, improvements in these 
symptoms would constitute an improvement in patients’ CC overall, and PRO items 
addressing these symptoms were found to be clear and comprehensive. CONCLU-
SIONS: Patient input is vital to identify the full spectrum of symptoms, and to 
determine an optimal set of clinical trial endpoints. Interview results suggest that a 
variety of techniques may be necessary to demonstrate concept saturation and identify 
those symptoms which accurately represent a functional disorder such as CC.
PGI30
PSYCHOMETRIC PROPERTIES OF THE TREATMENT SATISFACTION 
QUESTIONNAIRE FOR MEDICATION IN PATIENTS WITH 
GASTROESOPHAGEAL REFLUX DISEASE
Bharmal M1, Cascade E2, Gemmen E1
1Quintiles, Falls Church, VA, USA, 2iGuard, Falls Church, VA, USA
OBJECTIVES: The Treatment Satisfaction Questionnaire for Medication Version 1.4 
(TSQM) is a widely used 14-item generic instrument to assess patients’ satisfaction with 
medication, providing scores on four scales—Effectiveness, Side Effects, Convenience 
and Global Satisfaction. The objectives of this study were to assess the psychometric 
properties of the TSQM in a community-based population in the US receiving treat-
ments for gastroesophageal reﬂux disease (GERD). METHODS: Patients were 
recruited for this study from multiple sources including physician, pharmacy and online 
referrals to a medication monitoring service (www.iGuard.org). A random sample of 
patients using GERD treatments were invited to complete the TSQM online. Internal 
consistency of the TSQM scales was evaluated using item-total correlations and Cron-
bach’s alpha. Known-group validity was evaluated using analysis of covariance models 
based on the association of TSQM scale scores with a global item of patient rating the 
effectiveness of their medication. RESULTS: Data from a total of 1872 patients with 
at least one non-missing TSQM scale score were analyzed for this study. The mean (SD) 
age was 54.3 (12.4) years, 71.6% were females, 15.1% reported mild, 53.2% reported 
moderate and 31.7% reported severe disease severity. The TSQM scales had very good 
internal consistency, all item-total correlations were greater than 0.60. Cronbach’s 
alpha for Effectiveness scale was 0.92, Side Effects scale was 0.89, Convenience scale 
was 0.83 and Global Satisfaction scale was 0.89. After adjusting for patient age, gender, 
self-reported severity, GERD therapeutic class and number of concomitant medica-
tions, as expected, all the TSQM scales scores were signiﬁcantly associated with the 
global rating for medication effectiveness (all p < 0.0001), with higher TSQM scores 
among patients who believed that their medication completely cured their condition 
compared to those who rated medication effectiveness lower. CONCLUSIONS: The 
study provides evidence that the TSQM is a psychometrically sound and valid measure 
to assess patient satisfaction with GERD medication.
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OBJECTIVES: There are multiple potential sources of pain in liver transplant (txp) 
pts with consequences of delayed healing, higher health care costs and decreased 
quality of life. The objective of this study was to assess the incidence, quality, manage-
ment and treatment satisfaction of pain after liver txp. METHODS: This was a 
cross-sectional analysis of ambulatory liver txp pts. A questionnaire was developed 
using a modiﬁed Brief Pain Inventory. Pts described location, intensity, and pain 
quality. Pain symptoms were categorized as neuropathic, nociceptive and mixed pain. 
RESULTS: Sixty-eight pts were surveyed. Eleven pts were within 3 months of txp 
(Group 1) and 57 pts were > 3 mos post txp, mean of 60 ± 59 mos (Group 2). There 
were 38 males, 30 females; 10 AA, 58 Cauc; mean age 56 ± 9 yr. Forty-three pts 
(63%) reported having pain today: 90% of Group 1 and 58% of Group 2. Sixty-two 
percent of their pain was reported as new since txp. Forty-six percent of pain was 
nociceptive, 12% neuropathic and 42% mixed. Pain was most often in the lower 
extremities and lower back. Current pain was reported as being 4.5 (median) on a 
scale of 1–10. Pain interfered with sleep and normal work. Thirty-four pts were taking 
pain medications. Of these, more than 50% were taking 2 or more medication classes. 
Only 5 pts were being followed by a pain specialist, but 80% of these were completely 
satisﬁed with their pain management compared to 55% when followed by primary 
care and 40% when followed by the transplant team. CONCLUSIONS: Half of pts 
post liver txp have pain that impacts their lives and most often requires long term 
medication use for pain relief. Pts followed by pain specialists are more satisﬁed with 
their management than those followed by other health care providers.
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OBJECTIVES: To understand how multiple health outcomes (HO) instruments could 
better measure health-related quality of life (HRQoL) and work productivity in ulcera-
tive colitis (UC) patients, we examined interrelations among three HO instruments 
used in a clinical trial: a generic measure (SF-12v2), a disease speciﬁc measure (Short-
ened Inﬂammatory Bowel Disease [IBD] Questionnaire [SIBDQ]), and a work produc-
tivity measure (Work Productivity and Activity Impairment Questionnaire for UC 
[WPAI : UC]). METHODS: Mild-to-moderate UC patients received MMX mesalamine 
daily for 8 weeks in an open-label study. HO was measured at baseline and eight-
weeks. SF-12v2 measures 8 domains of generic HRQoL. SIBDQ measures 4 domains 
of IBD-related QoL: bowel symptoms, systemic symptoms, emotional function, and 
social function. The WPAI : UC measures 4 dimensions of work-related productivity 
impacted by UC: absenteeism, presenteeism, work impairment, and activity impair-
ment. Repeated-measures ANOVAs examined changes in HO scores. Associations 
among instruments in detecting HO change were assessed by intercorrelations among 
change scores, and correlations with patient-reported symptoms: bowel movement 
frequency (BMF) and rectal bleeding severity (RBS). RESULTS: 107 patients com-
pleted both assessments. Improvement occurred in 18 of 19 HO scale and summary 
scores (p < 0.05 for differences), indicating each instrument was responsive to treat-
ment. Correlations indicated moderate associations in the predicted directions for 
change scores among all three instruments: the average correlation was 0.47 between 
SF-12v2 and SIBDQ scales, −0.39 between SF-12v2 and WPAI : UC scales, and −0.48 
between SIBDQ and WPAI : UC scales. Improvement in scale scores for all measures 
was moderately correlated with improvement in both BMF and RBS (magnitude of 
average correlations ranged from 0.29 to 0.47). CONCLUSIONS: Instruments meas-
uring different aspects of HO showed consistent responsiveness to eight weeks’ treat-
ment with MMX mesalamine in mild-to-moderate UC patients. Similar results 
obtained using different HO instruments conﬁrm the treatment effect, and also indi-
cate convergent validity among these instruments within this patient population.
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OBJECTIVES: To conduct a systematic review of studies reporting primary hrQoL 
data among patients with Hepatitis C and assess implications for adherence, work 
